25th Annual Market Access Summit 2026 | Day 1

Gain insight into today’s sessions so you can get the most out of your conference experience.

Enhance your progress and impact delivered in the first phase of the 2023–2030 strategy. You’ll walk away with a blueprint to: 

• Bolster how global policy and geopolitical shifts are influencing strategic direction.
• Leverage how to embed new forms of evidence in practice for HTA and access.
• Ensure you understand how evidence expectations are evolving across payers, regulators, and industry.
• Master what interested parties should anticipate from Canada’s Drug Agency through to 2030.

 Gain clarity on progress to date and how embedding new forms of evidence will redefine access and decision-making through 2030.

Value recognition is a critical factor in Canada’s ability to attract and sustain access to innovative medicines.  HTA agencies are fundamental to establishing value recognition by acting as system conveners and bringing together all stakeholders to create a foundational understanding of value that is incorporated into carried through the entire reimbursement process.  Take away actionable strategies to help you:

• Explore how HTA frameworks are evolving to more fully and accurately capture the value of innovation, and examine what adaptations are needed to remain relevant, transparent, and impactful in a rapidly changing healthcare environment.

• Examine how value recognition established through HTA is leveraged by payers and how the alignment between HTA assessments and provincial reimbursement decisions can be strengthened to support both timely patient access and system sustainability.

Understand trends in value recognition and strengthen your submission for reimbursement – it has never mattered more.

Identify how IRP frameworks are evolving under increasing global pressure and what MFN policies change vs. traditional reference pricing. Create a roadmap to: 

• Eliminate the risk of accelerated price convergence across markets.
• Master the implications for Canadian pricing strategy and global positioning.
• Master how you adapt to manage pricing corridors and spillover risk.

 Identify the implications for your launch sequencing, price sustainability, and navigating increasing cross-market dependencies.

Ensure navigating specialized pathways and planning for the future is possible. It’s about moving beyond temporary “work-sharing” experiments to an integrated, permanent regulatory ecosystem that supports long-term launch predictability. Walk away with a blueprint to:

• Master the paediatric access revolution by evaluating the new federal pathways and legislative incentives to accelerate paediatric-specific treatments.
• Optimize regulatory modernization for rare diseases by analyzing how Health Canada is adapting evidence requirements for small patient populations and limited clinical trial data.
• Achieve data sovereignty & RWE by determining how Health Canada is utilizing real-world evidence (RWE) to support post-market surveillance.

Walk away with a roadmap for aligning your 2027 clinical and regulatory strategy with Canada’s increasingly agile, patient-centric, and specialized approval landscape.

Master the 2026 negotiation logic that requires an understanding of specific criteria. Apply new approaches to how you can determine negotiation prioritization. You’ll walk away with a blueprint to:

• Transform high-cost and curative therapies, including how the pCPA is adapting its financial risk-sharing models.
• Enhance system integration and address the friction points and opportunities for better alignment between CDA-AMC and active pCPA negotiations.
• Bolster lifecycle negotiations using the Alliance’s perspective on “renegotiation” triggers and managing products.

Identify the tactical adjustments and evidence requirements necessary for your manufacturers to achieve successful, predictable outcomes in an increasingly complex and scrutinized payer environment.

• Browse through different sponsor booths and source innovative market access expertise.
• Enter your name for a chance to win exciting prizes.
• Take advantage of event-specific offers and special content.

The CUSMA trade talks and the National Pharmacare program that is fragmented and seemingly stalled have introduced considerable uncertainty into the marketplace and the path forward.  Gain a better understanding of the impact on manufacturers and how private insurers may respond.  Take away ideas to:

• Assess the impact this uncertainty has on allocating coverage of some medications between national pharmacare where it exists and private plans
• Determine what impact Trump’s MFN call could have on manufacturer’s pricing decisions and the approach private insurers may take in response
• How private payers can improve plan sustainability
• Understand what drugs and therapies private payers will continue to cover and their listing criteria to enhance your submissions

Develop a solid submission strategy that addresses private payer challenges.

Expand your understanding of how ongoing funding is contingent on real-world clinical performance. Master how RWE in lifecycle management involves navigating the shift toward HTA reassessments. You’ll walk away with practical tips to:

• Heighten the generative AI leap by analyzing the role of AI in evidence packages, automating economic modelling, and streamlining pCPA negotiation prep.
• Enhance data interoperability challenges by overcoming the fragmentation of Canadian health data.
• Optimize governance and ethics by addressing payer concerns regarding the reimbursement process.

 Determine the strategic investments and multi-stakeholder partnerships required for you to transition from reactive data collection to a proactive, AI-enabled evidence strategy.

Engage in a deep dive into the modern value hierarchy. Better understand how payers now weigh comparative clinical effectiveness against long-term system sustainability and patient-reported outcomes. Walk away with actionable tips to:

• Bolster how you navigate the “Great Divide” using strategies for harmonizing disparate data requirements between INESSS (Quebec) and the CDA-AMC (ROC).
• Master the “Evidence Gap” in 2027 planning by identifying the missing links in the current dossier around real-world interoperability between provincial silos.
• Enhance predictive access analytics by leveraging advanced modelling to demonstrate value for high-cost, short-term treatment cycles in a multi-year budget framework.
• Transform societal and equity data and evaluate the growing role of “non-clinical” evidence in reimbursement decisions.

 Identify the strategic evidence-generation shifts required to align your value proposition with the specific, evolving drivers of Canadian payer decision-making. 

Examine the IQSSS decision matrix and analyze the operational changes in the drug evaluation process. Optimize how you navigate the transition to IQSSS. Adopt best practices to: 

• Impact the new institute’s mandate on HTA timelines and transparency.
• Improve “social and preventive” value, benchmarking the increased weighting of public health data and disease prevention.
• Transform the 2027 submission cycle by identifying critical success factors for new drug submissions.
• Amplify santé Québec and institutional governance, evaluating the new relationship in drug procurement and hospital access.
• Enhance the “Quebec Advantage” by formulating strategies to preserve accelerated access timelines within its modernized health and social services infrastructure.

 Determine the requirements for recalibrating Quebec market access strategies to ensure your continuous alignment with the province’s evolving HTA leadership and fiscal priorities.

• Experience the next level of market access innovation firsthand.
• Meet one-on-one with leading solution providers to discuss organizational hurdles.
• Brainstorm solutions and gain new perspectives and ideas.

Timely patient access and a value-based proposal can coexist. Advance your understanding of risk-sharing and value-based contracts. Walk away with actionable tips to:

• Bolster proven performance models by evaluating which risk-sharing structures, financial vs. outcomes-based, are being used.
• Optimize data infrastructure requirements and address the gaps in provincial health data.
• Amplify the payer perspective on risk and better understand how provincial ministries define and mitigate “uncertainty” in curative therapies.
• Improve administrative feasibility and streamline the monitoring and reconciliation processes.

 Determine the core components of a successful value-based proposal that satisfies your fiscal requirements of the pCPA while ensuring timely patient access.

Transform and reduce time-to-market in Canada. Examine how international fast-track models can provide you with valuable lessons that can drastically increase success. Source practical tips to:

• Optimize the international “Fast-Track” by evaluating how accelerated access models in the UK, EU, and Australia are reducing time-to-market.
• Advance global pricing benchmarking, analyzing the impact of international reference pricing shifts on Canadian PMPRB strategies.
• Excel innovative funding cross-pollination by adapting successful outcomes-based payment models from international markets.
• Master harmonized evidence standards leveraging global RWE and HTA data to strengthen local submissions.

Translate global market access successes into actionable, local initiatives that expedite patient access and improve your portfolio viability in the Canadian market.

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!